Asklepios BioPharmaceutical, Inc.

LEI 52990041V02U4BTXDI11

Legal Address [en-US]


c/o CORPORATION SERVICE COMPANY, 251 Little Falls Drive
Wilmington US-DE US 19808

Headquarters Address [en-US]


20 TW ALEXANDER DRIVE
DURHAM US-DE US 27709

LEI Registration Details
L E I
52990041V02U4BTXDI11
Legal Name
Asklepios BioPharmaceutical, Inc.
Authority Authority I D
RA000602
Authority Authority I D
7360795
Legal Jurisdiction
US-DE
Legal Form Legal Form Code
XTIQ
Status
ACTIVE
Initial Date
2020-12-10 05:02:50
Last Update Date
2021-11-30 14:01:43
Status
ISSUED
Next Renewal Date
2022-12-10 05:02:50
Managing L O U
5299000J2N45DDNE4Y28 [Herausgebergemeinschaft Wertpapier-Mitteilungen Keppler, Lehmann GmbH & Co. KG]
Validation Sources
FULLY_CORROBORATED
Validation Authority Validation Authority I D
RA000602
Validation Authority Validation Authority I D
7360795

Subsidiaries and Parent Companies

Parent / Holding Companies


Relationship Details

Business Entity Relationship

Active

Asklepios Biopharmaceutical, Inc. is directly consolidated by Bayer Aktiengesellschaft

Relationship Start Node Node I D
52990041V02U4BTXDI11 [Asklepios BioPharmaceutical, Inc.]
Relationship End Node Node I D
549300J4U55H3WP1XT59 [Bayer Aktiengesellschaft]
Relationship Relationship Type
Is Directly Consolidated By
Relationship Relationship Status
Active
Registration Initial Registration Date
2020-12-10 05:02:49
Registration Last Update Date
2020-12-10 05:02:50
Registration Registration Status
Published
Registration Next Renewal Date
2021-12-10 05:02:50
Registration Managing L O U
5299000J2N45DDNE4Y28 [Herausgebergemeinschaft Wertpapier-Mitteilungen Keppler, Lehmann GmbH & Co. KG]
Registration Validation Sources
Entity Supplied Only
Registration Validation Documents
Other Official Documents
Relationship Period 1 Start Date
2018-12-31 18:00:00
Relationship Period 1 End Date
2019-12-30 18:00:00
Relationship Period 1 Period Type
Accounting Period
Relationship Period 2 Start Date
2020-12-09 18:00:00
Relationship Period 2 Period Type
Relationship Period
Relationship Period 3 Start Date
2020-02-18 18:00:00
Relationship Period 3 Period Type
Document Filing Period

Business Entity Relationship

Active

Asklepios Biopharmaceutical, Inc. is ultimately consolidated by Bayer Aktiengesellschaft

Relationship Start Node Node I D
52990041V02U4BTXDI11 [Asklepios BioPharmaceutical, Inc.]
Relationship End Node Node I D
549300J4U55H3WP1XT59 [Bayer Aktiengesellschaft]
Relationship Relationship Type
Is Ultimately Consolidated By
Relationship Relationship Status
Active
Registration Initial Registration Date
2020-12-10 05:02:49
Registration Last Update Date
2020-12-10 05:02:50
Registration Registration Status
Published
Registration Next Renewal Date
2021-12-10 05:02:50
Registration Managing L O U
5299000J2N45DDNE4Y28 [Herausgebergemeinschaft Wertpapier-Mitteilungen Keppler, Lehmann GmbH & Co. KG]
Registration Validation Sources
Entity Supplied Only
Registration Validation Documents
Other Official Documents
Relationship Period 1 Start Date
2018-12-31 18:00:00
Relationship Period 1 End Date
2019-12-30 18:00:00
Relationship Period 1 Period Type
Accounting Period
Relationship Period 2 Start Date
2020-12-09 18:00:00
Relationship Period 2 Period Type
Relationship Period
Relationship Period 3 Start Date
2020-02-18 18:00:00
Relationship Period 3 Period Type
Document Filing Period


© 2025 LEI.report | Privacy Policy | LEI Resources
JP | LI | CZ | CH | AU | PL | IE | VG | KY | NO | AT | IN | FI | BE | CA | LU | SE | DK | FR | ES | NL | IT | DE | GB | US | HK |